Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial

• Published in: Current medicinal chemistry Vol. 20; no. 10; p. 1323
• Main Authors: Bo, S, Ciccone, G, Castiglione, A, Gambino, R, De Michieli, F, Villois, P, Durazzo, M, Cavallo-Perin, P, Cassader, M
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.03.2013
• Subjects: Adult; Anti-Inflammatory Agents - therapeutic use; Antioxidants - pharmacology; Antioxidants - therapeutic use; C-Reactive Protein - analysis; Cardiovascular Diseases - prevention & control; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Female; Humans; Inflammation - prevention & control; Male; Middle Aged; Oxidative Stress - drug effects; Placebo Effect; Resveratrol; Risk Factors; Smoking; Stilbenes - pharmacology; Stilbenes - therapeutic use; Triglycerides - blood
• ISSN: 1875-533X
• DOI: 10.2174/0929867311320100009

Smokers are characterized by a low-grade systemic inflammatory state and an oxidant-antioxidant imbalance. Few human studies were conducted on the effects of resveratrol, a natural compound with anti-inflammatory and antioxidant properties, and no trial on smokers has been performed to date. We evaluated whether resveratrol has beneficial effects on markers of inflammation and oxidative stress in smokers. A randomized, double- blind, cross-over trial was performed in 50 healthy adult smokers: 25 were randomly allocated to "resveratrol-first" (30-days: 500mg resveratrol/day, 30-days wash-out, 30-days placebo) and 25 to "placebo-first" (30-days placebo, 30-days wash-out, 30-days 500mg resveratrol/day). Resveratrol significantly reduced C-reactive protein (CRP) and triglyceride concentrations, and increased Total Antioxidant Status (TAS) values. After analyzing data with general linear models to assess period and carry-over effects, the ratios of the values after resveratrol to those after placebo were respectively: 0.47 (95%CI 0.38-0.59) -CRP- and 0.71 (95%CI 0.65-0.78) -triglycerides-, while TAS increased by 74.2 μmol/L (95%CI 60.8-87.6). Uric acid, glucose, insulin, cholesterol, liver enzyme concentrations, and weight, waist circumference, and blood pressure values did not significantly change after resveratrol supplementation. Because resveratrol has anti-inflammatory, anti-oxidant, and hypotriglyceridemic effects, its supplementation may beneficially affect the increased cardiovascular risk of healthy smokers.